Invivo Therapeutics Holdings Corp (NASDAQ:NVIV)’s share price shot up 18.2% during trading on Wednesday . The company traded as high as $0.95 and last traded at $0.91. 587,500 shares were traded during mid-day trading, an increase of 5% from the average session volume of 558,700 shares. The stock had previously closed at $0.77.
The company has a debt-to-equity ratio of 0.04, a current ratio of 5.06 and a quick ratio of 5.06. The stock has a market capitalization of $26.36, a P/E ratio of -0.91 and a beta of 3.21.
Invivo Therapeutics (NASDAQ:NVIV) last announced its quarterly earnings data on Monday, October 30th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.22) by ($0.06). analysts anticipate that Invivo Therapeutics Holdings Corp will post -0.81 EPS for the current year.
Institutional investors have recently made changes to their positions in the company. Blair William & Co. IL purchased a new stake in shares of Invivo Therapeutics in the 2nd quarter valued at $159,000. Susquehanna International Group LLP purchased a new stake in shares of Invivo Therapeutics in the 2nd quarter valued at $434,000. Goldman Sachs Group Inc. boosted its stake in shares of Invivo Therapeutics by 144.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 167,318 shares of the biotechnology company’s stock valued at $452,000 after purchasing an additional 98,879 shares in the last quarter. Finally, Legal & General Group Plc boosted its stake in shares of Invivo Therapeutics by 4,427.9% in the 2nd quarter. Legal & General Group Plc now owns 503,407 shares of the biotechnology company’s stock valued at $1,359,000 after purchasing an additional 492,289 shares in the last quarter. 12.84% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY WARNING: “Invivo Therapeutics (NVIV) Shares Up 18.2%” was originally reported by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://transcriptdaily.com/2018/01/05/invivo-therapeutics-nviv-shares-up-18-2.html.
Invivo Therapeutics Company Profile
InVivo Therapeutics Holdings Corp., formerly Design Source, Inc, is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company’s approach to treating acute SCIs is based on its investigational Neuro Spinal Scaffold implant, an investigational bioresorbable polymer scaffold that is designed for implantation at the site of injury within a spinal cord contusion and is intended to treat acute spinal cord injury.
Receive News & Ratings for Invivo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.